WESTBOROUGH, Mass., Aug. 4 /PRNewswire/ -- Three quarters of bench
scientists, industry leaders and pharmaceutical executives believe the United
States should allow the cloning of human cells, according to a new survey
released today by IBC Life Sciences. The survey measured industry views on
current trends and issues in drug discovery and technology.
Of the 468 drug discovery professionals surveyed, 72 percent said that the
United States should pass legislation allowing the cloning of human cells to
make embryonic stem cells for use in research. Only 13 percent disagreed, and
15 percent said they were undecided on the topic of cloning.
The stem cell results were just one of several intriguing findings of the
IBC Life Sciences Survey, which was conducted last month in advance of 10th
Annual IBC Life Sciences' Drug Discovery Technology(R) & Development World
Congress, August 8-11, 2005 in Boston, Massachusetts.
"Numerous public opinion polls have been conducted on drug discovery
topics, but very few surveys have measured the views of the professionals
working in the industry's labs and boardrooms," said Ellen Massa, marketing
director at IBC Life Sciences.
"Our survey found that industry professionals are skeptical of the hype
surrounding nanotechnology-enabled drug delivery systems, for example. In
fact, many scientists and industry leaders identified protein therapeutics as
having the best growth potential in the next few years. A significant
percentage said they are expecting a decrease in the costs associated with
drug development," Massa added.
Highlights of some of the survey findings include:
* Some analysts believe nanotechnology-enabled drug delivery systems will
generate revenues of more than $1.7 billion in 2009 and more than $4.8
billion in 2012. But, according to the IBC Life Sciences, 66 percent
believe those revenue predictions are overstated. Thirty-one percent
said analysts are on target and three percent described expert
expectations are too pessimistic.
* More than one-third of those surveyed (34 percent) chose protein
therapeutics as the category of drugs that will experience the highest
growth in the next five years, followed by small molecules (27 percent)
and antibody therapeutics (25 percent). Only nine percent indicated
that vaccines would foresee the highest growth.
* Currently, the average drug development process takes 15 years and costs
between $800 million and $1.7 billion. Approximately 40 percent of the
industry scientists and professionals surveyed expect these costs will
decrease. More than one-third (33 percent) said they expect drug
development costs will increase over the next five years.
Survey respondents also answered questions regarding barriers in drug
research and development; the FDA's new Critical Path Initiative; and,
technologies that have significantly impacted drug research or development and
companies' shift from drug discovery to drug development. A complete list of
questions and survey results is available at http://www.drugdisc.com/survey.
In addition to conducting this survey on drug discovery and technology,
IBC Life Sciences' Drug Discovery Technology(R) & Development World Congress
will address several topics on the recent trends in drug discovery. FDA
Commissioner, Dr. Lester Crawford will be the keynote speaker and additional
sessions will be led by key industry leaders such as, Dr. John L. LaMattina,
President of Pfizer Global Research and Development and Dr. Robert R. Ruffolo,
Jr., President of research and development at Wyeth Pharmaceuticals.
About 10th Anniversary Drug Discovery Technology(R) & Development World
The Drug Discovery Technology(R) & Development World Congress is designed
for drug discovery researchers and business executives to evaluate and
understand the latest scientific, business and informatics advances in drug
discovery research. In addition to a full conference program of speakers and
keynotes, this event features an exhibit hall of 350+ exhibit booths
showcasing the newest technologies and products that are driving the drug
discovery field. Drug Discovery Technology(R) & Development 2005 will be held
August 8-11, 2005 at Boston Convention & Exhibition Center in Boston, MA. For
conference details, visit http://www.drugdisc.com/us.
Free exhibit hall and keynote passes are available through Friday, August
5 at http://www.drugdisc.com/pass.
About IBC Life Sciences
IBC Life Sciences is an independent organizer that is in business to
provide an unbiased forum for the evaluation of current research, market
trends, technological developments and applications. IBC Life Sciences is part
of IBC USA Conferences, Inc., part of The Informa Group plc (London: INF). The
Informa Group has been a publisher and event organizer in the life sciences
industry for over 20 years. IBC USA Conferences is headquartered in
For questions contact:
IBC USA Conferences
Senior Marketing Manager
Telephone: (508) 616-5550 Ext. 213
SOURCE IBC Life Sciences